Health Canada approves Zolgensma, the one-time gene therapy for paediatric patients with spinal muscular atrophy

16 December 2020 - Zolgensma is designed to address the genetic root cause of SMA by replacing the missing or defective ...

Read more →

Health Canada approves first-ever gene replacement therapy, Luxturna

15 October 2020 - Luxturna (voretigene neparvovec), is the first approved therapy for previously untreatable inherited retinal disease. ...

Read more →

Alnylam launches Onpattro (patisiran) for the treatment of polyneuropathy in hATTR amyloidosis, the first-ever RNAi therapeutic approved in Canada

23 July 2019 - Onpattro is the only treatment that demonstrated improvement, relative to baseline, in both polyneuropathy and quality ...

Read more →

Akcea and Ionis announce approval of Tegsedi (inotersen injection) in Canada

4 October 2018 - First and only treatment of its kind for Canadians with hereditary transthyretin-mediated amyloidosis with polyneuropathy – a ...

Read more →

Alnylam Pharmaceuticals receives priority review in Canada for patisiran, an investigational RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy

24 September 2018 - Health Canada grants priority review to promising medicines intended for the treatment of serious, debilitating or life-threatening ...

Read more →

Biogen's Spinraza (nusinersen) receives Notice of Compliance from Health Canada for the treatment of 5q spinal muscular atrophy

4 July 2017 - First SMA treatment approval in Canada. ...

Read more →